Scintigraphic imaging with a peptide glucuronide in rabbits: 99mTc- exorphin C glucuronide

Applied Radiation and Isotopes

Volumn 65, Issue 2, 2007, Pages 170-175

  Ertay, T ^a   Unak P ^b   Biber, F Z ^a   Tasci, C ^a   Zihnioglu F ^b   Durak, H ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

99mTc GE; 99mTc GEG; 99mTc labeled peptides; Exophin C; Exophin C glucuronide; Scintigraphy

Indexed keywords

DIAGNOSIS; ISOTOPES; LIVING SYSTEMS STUDIES; POLYPEPTIDES; TUMORS;

99MTC-GE; 99MTC-GEG; EXOPHIN C; EXOPHIN C GLUCURONIDE; SCINTIGRAPHY;

MEDICAL IMAGING;

CHELATING AGENT; GLUCEPTATE TC 99M; GLUCOHEPTONATE EXOPHIN C GLUCURONIDE TECHNETIUM 99 M; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER; CELL LABELING; CHELATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SCINTIGRAPHY;

ANIMALS; BRAIN; FEMALE; GLUCURONIDES; HEMOGLOBINS; MALE; MICROSOMES; MICROSOMES, LIVER; ORGANOTECHNETIUM COMPOUNDS; PEPTIDE FRAGMENTS; RABBITS; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; RECEPTORS, OPIOID; SUGAR ACIDS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 37849188849     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2006.03.017     Document Type: Article

References (24)

1. Adams S., Baum R., Rink T., Schumm-Drager P.M., Usadel K.H., and Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur. J. Nucl. Med. 25 (1998) 79-83
2. Andreotti A.H., and Kahne D. Effects of glycosylation on peptide backbone conformation. J. Am. Chem. Soc. 115 (1993) 3352-3353
3. Behr T.M., Gotthardt M., Barth A., and Behe M. Imaging tumors with peptide-based radioligands. Q. J. Nucl. Med. 45 (2001) 189-200
4. Bradford M.M. A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Buchwald P., and Bodor N. Octanol-water partition of nonzwitterionic peptides: predictive power of a molecular size-based model. PROTEINS: Structure, Function and Genetics 30 (1998) 86-99
6. 99mTc-Exorphin C on rabbits. Appl. Radiat. Isot. 62 (2005) 883-888
7. Fischman A.J., Babich J.W., and Strauss W.H. A ticket to ride: peptide radiopharmaceuticals. J. Nucl. Med. 34 (1993) 2253-2263
8. Friedmann Y., Vlodavsky H., Aingorn H., Aviv A., Perets T., Pecker I., and Pappo O. Expression of heperanase in normal, dysplastic and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumourigenesis. Am. J. Path. 157 (2000) 1167-1175
9. Fukudome S., and Yoshikawa M. Gluten Exorphin C. A novel opioid peptide derived from wheat gluten. FEBS Lett. 316 (1993) 17-19
10. Fukudome S., Jinsmaa Y., Matsukawa T., Sasaki R., and Yoshikawa M. Release of opioid peptides, gluten exorphins by the action of pancreatic elastase. FEBS Lett 412 (1997) 475-479
11. Heppeler A., Froidevaux S., Eberle A.N., and Maecke H.R. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr. Med. Chem. 7 (2000) 971-991
12. Hollosi M., Perczel A., and Fasman G.D. Cooperativity of carbohydrate moiety orientation and beta-turn stability is determined by intramolecular hydrogen bonds in protected glycopeptide models. Biopolymers 29 (1990) 1549-1564
13. Kellam B., Drouillat B., Dekany G., Starr M.S., and Toth I. Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents. Int. J. Pharm. 161 (1998) 55-64
14. Kessler H., Matter H., Gemmecker G., Kottenhahn M., and Bats J.W. Effects of glycosylation on peptide backbone conformation. J. Am. Chem. Soc. 114 (1992) 4805-4818
15. Lister-James J., Moyer B.R., and Dean T. Small peptides radiolabelled with Tc-99m. Q. J. Nucl. Med. 40 (1996) 221-233
16. Maeji N.J., Inoue Y., and Chuo R. Conformational study of O-glycosylated threonine containing peptide models. Int. J. Pept. Protein Res. 29 (1987) 699-707
17. Reubi J.C. In vitro identification of vasoactive peptide receptors in human tumors: implications for tumor imaging. J. Nucl. Med. 36 (1995) 1846-1853
18. Schmidt F., and Monneret C. Prodrug mono therapy: Synthesis and biological evaluation of an etoposide glucuronide-prodrug. Bioorg. Med. Chem. 11 (2003) 2277-2283
19. Sperker B., Backman J.T., and Kroemer H.K. The role of beta-glucuronidase in drug disposition and drug targeting in humans. Clin. Pharm. 33 (1997) 18-31
20. Sperker B., Werner U., Murdter T.E., Tekkaya C., Fritz P., Wacke R., Adam U., Gerken M., Drewelow B., and Kroemer H.K. Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting. Naunyn-Schmiedebergs Arch. Pharmacol. 362 (2000) 110-115
21. Stevenson D.E. Optimisation of UDP-glucuronyl transferase-catalysed synthesis of testosterone-β-D-glucuronide by inhibition of contaminating β-glucuronidase. Biotechnol. Tech. 13 (1999) 17-21
22. Unak T., Avcibasi U., Yildirim Y., and Cetinkaya B. Attempts to develope a new nuclear measurement technique of beta-glucuronidase levels in biological samples. Czech. J. Phys. 53 (2003) A797-A802
23. Virgolini I., Yang Q., Li S., Angelberger P., Neuhold N., and Niederle B. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membran receptors. Cancer Res 54 (1994) 690-700
24. Zihnioǧlu, F., 1992. Isolation, purification and immobilization of UDP-GLUCUROYL TRANSFERASE, Ph.D. Thesis, Ege University Graduate School of Natural and Applied Sciences, Chemistry Department, Biochemistry Section, Bornova, Izmir, Code No. 10.0600.0000.68, p. 169.